The commercialisation agreements for the biosimilar to aflibercept (Eylea) cover Israel, major parts of Europe and the Asia-Pacific Region
The launch follows a CE Mark received in late 2024
The study built on previous research indicating specific retinal variables can serve as disease-related biomarkers in neurodegenerative diseases
The authors investigated systemic adverse events associated with commercial mydriatics administered during retinopathy of prematurity (ROP) screening
ViGeneron, based in Munich, also received approval for dose escalation in the ongoing phase 1b clinical trial
Clinicians need to better understand how to reduce the growth of antibiotic-resistant, more virulent bacteria, the authors said
Investigators reported that the trial demonstrated significant improvements in visual function and retinal structure for patients with optic neuritis
In October, Oxular began a phase 2 trial for its therapeutic candidate OXU-001, for treatment of diabetic macular oedema
Patients with fibromyalgia experienced changes in the macular ganglion cell layer and retinal nerve fiber layer
The RESTORE Study is the follow-up study of the RESCUE and REVERSE studies of lenadogene nolparvovec to treat vision loss from LHON
Investigators emphasised the need for continued efforts to raise awareness and support patients in attending regular screening
Hot topics around the globe, from clinical trials to the solar eclipse
Highlights from the year, courtesy of our colleagues at Ophthalmology Times
Alcon Laboratories is voluntarily recalling one lot (Lot 10101) of its Systane Lubricant Eye Drops Ultra PF, Single Vials On-the-Go, 25 count, after identifying fungal contamination in a sealed vial.
The top therapeutic advancements in myopia, diabetes, dry eye and more
Trending topics and milestone stories from our year in ophthalmology
The number of patients with retinal vascular diseases is expected to increase over time due to the aging population and lifestyle changes
Our top 10 print stories highlight the core content concepts we explored this year
The Danish Medicines Agency requested the EMA's Pharmacovigilance Risk Assessment Committee review reports on the vision-threatening condition
Low-level light therapy for dry eye disease and chalazion
The timeline demonstrates international innovation and collaboration
Sophisticated programmes require an evolving mindset
Espansione Group's Light Modulation Low-level Light Therapy (LLLT) is used in ophthalmology and dermatology
Ocular clues to a neurological conditions help clinicians understand neuromyelitis optica spectrum disorder (NMOSD)
The European Commission will assess the marketing authorisation for Eydenzelt (reference product Eylea)
A confirmed diagnosis of familial exudative vitreoretinopathy aids in several aspects of patient management
The PFS is approved for treatment of neovascular age-related macular degeneration, diabetic macular oedema and macular oedema following retinal vein occlusion
Phenocell and Amarna Therapeutics were awarded the grant by Eureka’s Eurostars initiative, co-funded by the European Union
A retrospective study assessed elevated neutrophil-to-lymphocyte ratios and systemic immune-inflammation index levels in patients with different subtypes of DMO
The research findings supported the hypothesis that a mild reduction in retinal contrast can slow myopia progression in young children
